Skip to main content

Former Watson executive returns to co., appointed EVP global brands


MORRISTOWN, N.J. A generic pharmaceutical company has appointed a new executive to its branded drug division.

Watson Pharmaceuticals announced Monday the appointment of G. Frederick Wilkinson as EVP global brands. In the new position, Wilkinson will be responsible for “all aspects” of Watson’s global brand pharmaceutical business, including brand product development, global sales and marketing and coordinating brand product business development activities, as well as overseeing efforts by the company to develop biologics.

“Fred returns to Watson with an extraordinary record of accomplishments, having built a successful brand products business at Duramed Pharmaceuticals, the brand business of Barr Pharmaceuticals, particularly in the area of women’s healthcare,” Watson CEO Paul Bisaro said in a statement. “We will look to Fred to further strengthen our U.S. brand business, which includes a strong product portfolio supported by the recent launches of Rapaflo (silodosin) and Gelnique (oxybutynin chloride).”

This ad will auto-close in 10 seconds